February 18, 2026 07:14 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
AI takes centre stage as Modi meets Google CEO Sundar Pichai in Delhi | G7 Spotlight: Emmanuel Macron invites Narendra Modi for 2026 Summit | AI Summit embarrassment! Galgotias University asked to vacate stall after ‘own robot’ exposed as China’s Unitree Go2 | Actor Rajpal Yadav granted interim bail in ₹9-crore cheque bounce case | Learn AI or become redundant: Microsoft India President issues stark message | India’s wholesale inflation rises to 1.81% in January as manufacturing prices surge | 'India at forefront of AI revolution': PM Modi welcomes world leaders to Delhi summit | Rs 5,000 to women ahead of Tamil Nadu polls! Vijay slams Stalin, says: ‘take the money, blow the whistle’ | Modi congratulates Tarique Rahman as BNP clinches majority in Bangladesh polls | Bangladesh Polls: Tarique Rahman-led BNP secures 'absolute majority' with 151 seats in historic comeback
Johnson And Johnson Vaccine

Johnson & Johnson suspends COVID-19 vaccine trials in Brazil

| @indiablooms | Oct 14, 2020, at 02:54 pm

Brasilia/Xinhua: The Janssen-Cilag company, the pharmaceutical division of US multinational Johnson & Johnson, temporarily suspended clinical trials in Brazil of a vaccine against the novel coronavirus (COVID-19), the national health regulatory body Brazilian Health Surveillance Agency (Anvisa) said on Wednesday.

Janssen-Cilag notified Anvisa that testing to determine the safety and efficacy of its vaccine VAC31518COV3001 "was temporarily suspended due to a serious adverse occurrence in a volunteer abroad."

The company did not provide more details about the case, as the volunteer's health status is kept confidential.

According to Anvisa, the trials will not resume until there is an investigation into the cause of the problem by the Independent Safety Committee, as part of good clinical practice procedures.

"In Brazil, the inclusion of the first volunteer in the study occurred on Oct. 9 and new inclusions can only occur when there is authorization from Anvisa, which will proceed with the analysis of the research data and decide on the continuity or permanent suspension based on the safety and risk/benefit assessment," the agency said.

Janssen-Cilag received authorization from Anvisa in August to carry out the trials in Brazil.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.